MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
3.840
+0.170
+4.63%
After Hours: 3.970 +0.13 +3.39% 19:25 02/06 EST
OPEN
3.840
PREV CLOSE
3.670
HIGH
3.900
LOW
3.670
VOLUME
2.56M
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
2.705
MARKET CAP
738.52M
P/E (TTM)
-17.2973
1D
5D
1M
3M
1Y
5Y
1D
Arbutus Biopharma Secures Mixed Ruling in Moderna Patent Case
TipRanks · 1d ago
Arbutus Biopharma Announces U.S. District Court For The District of Delaware Issues Memorandum, Order In Litigation Filed Co. Against Moderna Over Patent Infringement
Benzinga · 1d ago
ARBUTUS BIOPHARMA CORP - U.S. COURT ISSUES MEMORANDUM IN ARBUTUS VS. MODERNA CASE - SEC FILING
Reuters · 1d ago
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts
Seeking Alpha · 4d ago
Arbutus faces higher bar to argue infringement by Moderna, says Jefferies
TipRanks · 5d ago
Moderna reverses lower after court issues memo in patent fight with Arbutus
TipRanks · 5d ago
Arbutus jumps on ruling in patent dispute with Moderna
Seeking Alpha · 5d ago
Moderna rises after Delaware court issues memo in patent fight with Arbutus
TipRanks · 5d ago
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.